QNTA - QNTA STOCK NEWS

Medolife Rx, a subsidiary of Quanta, Inc. (OTCQB: QNTA), announced a significant breakthrough in its polarization technology, revealing that polarized ibuprofen is 257% more effective at inhibiting the COX-2 enzyme compared to conventional ibuprofen.

This advancement could reduce drug dosages and side effects, with potential applications in various pharmaceuticals, including chemotherapy. The company seeks partnerships with major pharmaceutical companies to explore these opportunities further, while also pursuing regulatory approval for its product Escozine®.

Medolife Rx, a subsidiary of Quanta, Inc. (OTCQB: QNTA), has commenced a study to evaluate the effectiveness of its polarized cannabidiol (CBD) muscle rub in reducing inflammation by inhibiting COX-2 enzyme activity. Supervised by Dr. Elizabeth Singer from BCN Biosciences, the study aims to compare the polarized CBD's efficacy against non-polarized alternatives. Previous studies indicated a 591% increase in inhibition efficacy, with high-intensity polarized CBD achieving 71% COX-2 inhibition. If successful, the company may pursue regulatory approval for its pain relief products.

Quanta, Inc. (OTCQB: QNTA) subsidiary Medolife Rx, announced the successful completion of a bi-annual filing with the Dominican Republic's Ministry of Environment, detailing the expansion of its scorpion reservation. This expansion has surpassed regulatory expectations, positioning Escozine®, Medolife's lead drug candidate, as a promising treatment for COVID-19. The company aims to enhance peptide production through the reservation, which significantly reduces costs. Moreover, the MOE expressed interest in purchasing Escozine® for its employees, highlighting the product's therapeutic potential.

Medolife Rx, a subsidiary of Quanta (OTC PINK: QNTA), launched a successful digital advertising campaign on September 16, 2021, featuring skateboarder Tony Hawk as the product spokesperson for its Aelia line of pain management products. Following the campaign, the company reported a spike in web traffic and over 800% increase in unique sessions from Instagram. The global topical pain relief market is projected to reach $11.78 billion by 2025, aligning with Medolife's growth strategy in natural and effective remedies.

Medolife Rx, a majority-owned subsidiary of Quanta (OTC PINK: QNTA), announced clarifications regarding its preclinical studies for Escozine®, targeting COVID-19 and cancer treatments. Extensive research is underway to secure product registration in multiple countries, including the US, Dominican Republic, and Mexico. The company plans to expand registration efforts to Latin American markets like Brazil and Argentina through various health organizations.

Medolife Rx, a bioceutical firm and majority-owned subsidiary of Quanta (OTCQB: QNTA), received positive feedback from the Dominican Republic’s Ministry of Environment during a recent bi-annual visit to its Neyba province scorpion reservation. Established in 2008, this joint venture aims to ensure compliance with safety standards and enhance local welfare. The assessment confirmed proper scorpion care and worker training, underscoring the facility's socio-economic impact. The reservation supports peptide production for Medolife’s pharmaceutical offerings, including the COVID-19 candidate, Escozine, currently under FDA review.

Medolife Rx, a subsidiary of Quanta (OTC PINK: QNTA), reported its participation in the Tony Hawk’s Vert Alert event in Salt Lake City, where it showcased its rebranded wellness products, including pain relief options. Over 8,000 attendees included athletes who expressed enthusiasm for the products, which target sports-related injuries. Medolife aims to expand its partnership with Tony Hawk to reach more consumers. The company also introduced its new nutraceutical product, Immunapen™, addressing wellness challenges. The global topical pain relief market is projected to hit $11.78 billion by 2025.

Medolife Rx, a subsidiary of Quanta, Inc. (OTC PINK: QNTA), has announced its financial results for Q2 2021, reporting total revenue of USD $116,869 with gross margins above 60%. Cash reserves exceeded USD $277,000. Key operational updates include FDA feedback on its Escozine® drug, a product endorsement deal with Tony Hawk, and a distribution agreement for Mexico. The company has also re-registered Escozine® in the Dominican Republic as a natural medicine for oncological treatments and produced its first medical-grade batch.

Medolife Rx, a bio-pharmaceutical company, will participate in the "Tony Hawk’s Vert Alert" competition on August 27-28, 2021, in Salt Lake City, aiming to attract over 8,000 attendees. This event marks the relaunch of their Aelia product line, which includes polarized muscle rubs and new wellness products targeting various ailments. They will also introduce the Immunapen™, a product line designed to enhance immune function with its polarized scorpion peptide formulation. The brand partnership with Tony Hawk aims to extend their market reach and promote health products effectively.